Hospital
ST. Vincent's ST. Clair, LLC
ST. Vincent's ST. Clair, LLC was paid $2.44M by Medicaid between Jan 2018 and Nov 2024, across 55 billing codes. Its largest line is 99285, emergency room visit (most serious) — 31% of everything it billed.
33Billing provider infoST. VINCENT'S ST. CLAIR, LLC
PELL CITY, AL 35125
PELL CITY, AL 35125
33aNPI1992809305assigned 09/08/2006
33bProvider typeMedicare Defined Swing Bed Hospital Unit
28Total paid$2.44M
24GClaims52,735
24DCodes billed55
24AFirst – last monthJan 2018 – Nov 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 8,370 | $312K | |
| 2019 | 8,810 | $352K | |
| 2020 | 5,422 | $201K | |
| 2021 | 7,411 | $316K | |
| 2022 | 8,212 | $433K | |
| 2023 | 7,540 | $448K | |
| 2024incomplete | 6,970 | $383K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 31% | 2,639 | 2,463 | $756K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 26% | 8,846 | 8,289 | $626K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 21% | 12,154 | 11,598 | $509K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 9.9% | 2,423 | 2,330 | $243K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 3.8% | 1,914 | 1,772 | $92K |
| 80053 | Comprehensive metabolic panel | 2.4% | 5,208 | 4,802 | $59K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.3% | 6,279 | 5,780 | $57K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 519 | 501 | $19K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 478 | 468 | $19K |
| 87070 | <1% | 711 | 656 | $8K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 475 | 437 | $7K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 588 | 558 | $6K |
43 more codes
| 81025 | <1% | 1,775 | $6K | |
| 81001 | <1% | 1,360 | $5K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 52 | $5K |
| 83690 | <1% | 628 | $4K | |
| 71045 | Radiologic examination, chest; single view | <1% | 659 | $4K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 40 | $3K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 236 | $3K |
| 87634 | <1% | 44 | $2K | |
| 84484 | <1% | 139 | $1K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 31 | $1K |
| 83605 | <1% | 86 | $949.84 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 105 | $901.55 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 16 | $838.05 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 614 | $699.76 |
| 80061 | Lipid panel | <1% | 40 | $645.65 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 391 | $587.28 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 126 | $482.60 |
| 81003 | <1% | 181 | $448.58 | |
| 87420 | <1% | 27 | $433.08 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 25 | $427.57 |
| 83735 | <1% | 53 | $323.38 | |
| 85610 | <1% | 65 | $262.69 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 232 | $234.91 |
| 82150 | <1% | 30 | $222.06 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 16 | $188.72 |
| 82550 | <1% | 13 | $177.38 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 12 | $147.96 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 13 | $107.76 |
| 85027 | <1% | 15 | $92.17 | |
| 85730 | <1% | 39 | $91.06 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 226 | $42.26 |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 704 | $14.66 |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 83 | $11.93 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 538 | $7.80 |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 55 | $6.07 |
| J2704 | Injection, propofol, 10 mg | <1% | 371 | $4.15 |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 0% | 343 | $0.00 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | 0% | 274 | $0.00 |
| A9270 | Non-covered item or service | 0% | 501 | $0.00 |
| 96375 | Therapeutic injection; each additional sequential IV push | 0% | 94 | $0.00 |
| 36415 | Collection of venous blood by venipuncture | 0% | 65 | $0.00 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 0% | 162 | $0.00 |
| J1030 | Injection, methylprednisolone acetate, 40 mg | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialALEXANDER, JASON (CEO)
| Provider | Location | Paid |
|---|---|---|
| Clover Family Corp | Burlington, NC | $1.25M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.